View Older Stories
-
Stifel on Celcuity Inc (CELC) Amid 20% Selloff: 'We remain confident in PIK3CA-WT regulatory prospects'
-
Celcuity reports positive Phase 3 trial results for gedatolisib in breast cancer
-
Celcuity (CELC) Reiterated at Market Outperform by Citizens Ahead of ASCO Presentation
-
Celcuity (CELC) Reiterated at Market Outperform by Citizens Ahead of ASCO Data
-
Celcuity Inc (CELC) PT Raised to $185 at H.C. Wainwright
-
Celcuity Inc (CELC) PT Raised to $175 at Stifel
-
Celcuity (CELC) Tops Q1 EPS by 7c
-
Celcuity (CELC) call put ratio 1 call to 2.5 puts with a focus on May puts as share price up 16%
-
Increasing unusual option volume: TPG XRX FXY CGNX MRAM CRNC CELC SIMO
-
Celcuity Inc (CELC) PT Raised to $160 at Citizens
-
Celcuity Inc (CELC) PT Raised to $165 at Guggenheim
-
Celcuity Inc (CELC) PT Raised to $157 at Needham
-
Celcuity Inc (CELC) PT Raised to $150 at Stifel on PIK3CA Data
-
H.C. Wainwright Upgrades Celcuity Inc (CELC) to Buy
-
Citizens Starts Celcuity Inc (CELC) at Market Outperform
-
H.C. Wainwright Reiterates Neutral Rating on Celcuity Inc (CELC)
-
Celcuity Inc (CELC) PT Raised to $141 at Craig-Hallum
-
Celcuity Inc (CELC) PT Raised to $125 at Stifel on Reduced OpEx Estimates
-
Celcuity (CELC) Tops Q4 EPS by 32c
-
Wolfe Research Reiterates Outperform Rating on Celcuity Inc (CELC): "Relay's update does not appear to change the efficacy benchmark"
-
Celcuity Inc (CELC) PT Raised to $122 at Needham
-
Celcuity (CELC) 5K contracts of April 130 calls trade
-
Wolfe Research: 'We'd be buyers of CELC on any weakness related to the external catalyst'
-
Celcuity receives FDA acceptance for gedatolisib breast cancer drug
-
Jefferies lists 5 biotech M&A candidates for 2026
-
Celcuity Inc (CELC) PT Raised to $118 at Leerink Partners
-
Wells Fargo Starts Celcuity Inc (CELC) at Overweight
-
Celcuity Inc (CELC) PT Raised to $134 at Jefferies
-
Jefferies on Celcuity Inc (CELC): 'we believe everolimus+gire could be a good option specifically for the PIK3CAwt/ESR1mut subgrp'
-
Increasing unusual call option volume: EQG CELC BBD FE CWAN
-
Wolfe Research Starts Celcuity Inc (CELC) at Outperform
-
H.C. Wainwright Downgrades Celcuity Inc (CELC) to Neutral
-
Celcuity Inc (CELC) PT Raised to $115 at Stifel
-
Celcuity (CELC) Tops Q3 EPS by 10c
-
Increasing unusual call option volume: BBD BORR APLS VIAV ROIV FMC VITL RSI METU OWL FBL FI CELC
-
Guggenheim Starts Celcuity Inc (CELC) at Buy
-
Celcuity increases term loan facility to $500 million
-
Celcuity Inc (CELC) PT Raised to $66 at H.C. Wainwright
-
Celcuity Inc (CELC) PT Raised to $68 at Stifel
-
Celcuity Inc (CELC) PT Lowered to $70 at Needham
-
Celcuity Inc (CELC) PT Raised to $79 at Jefferies
-
Celcuity (CELC) Misses Q2 EPS by 16c
-
Celcuity Inc (CELC) PT Raised to $50 at H.C. Wainwright
-
Celcuity receives patent extending gedatolisib exclusivity to 2042
-
Stifel Assumes Celcuity (CELC) at Buy
-
Celcuity (CELC) Reports Clinical Data from Two Early Phase Studies of Gedatolisib
-
Celcuity (CELC) Misses Q1 EPS by 14c
-
Stifel Reiterates Buy Rating on Celcuity Inc (CELC)
-
Celcuity (CELC) Misses Q4 EPS by 4c
-
Celcuity Inc (CELC) PT Raised to $33 at Jefferies

